Ellberg Charlotte C, Schwartz Hannah, Witt Annika, McCowen Karen C, Fuentes Ana Lucia, Malhotra Atul
Department of Medicine, University of California, San Diego, La Jolla, CA USA.
Department of Medicine, Weill Cornell Medicine, New York, NY USA.
Curr Pulmonol Rep. 2025;14(1):19. doi: 10.1007/s13665-025-00384-1. Epub 2025 Jul 25.
Strong associations exist between obstructive sleep apnea (OSA) and obesity. Prior studies have demonstrated that weight reduction in people with OSA and obesity improves severity of OSA. Until recently, there were no approved pharmacotherapies for OSA. We aim to review recent literature on GLP-1 receptor agonists and GIP agonists and their potential role in the management of OSA.
Novel pharmacotherapies developed to target obesity include glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. These therapies have proven to be helpful in many comorbid conditions, with published studies suggesting a benefit in OSA.
GLP-1 receptor agonists and GIP agonists are emerging potential therapies for OSA and associated cardiometabolic risk.
阻塞性睡眠呼吸暂停（OSA）与肥胖之间存在密切关联。先前的研究表明，OSA合并肥胖者体重减轻可改善OSA的严重程度。直到最近，尚无获批用于治疗OSA的药物疗法。我们旨在综述有关胰高血糖素样肽-1（GLP-1）受体激动剂和葡萄糖依赖性促胰岛素多肽（GIP）受体激动剂及其在OSA管理中的潜在作用的最新文献。
针对肥胖开发的新型药物疗法包括GLP-1受体激动剂和GIP受体激动剂。这些疗法已被证明对许多合并症有帮助，已发表的研究表明对OSA有益。
GLP-1受体激动剂和GIP受体激动剂正在成为治疗OSA及相关心脏代谢风险的潜在疗法。
